Also uplisting to NYSE which will rocket PPS. We get above a dollar with FDA approval and more investors in that price range could take it up to 2 as this ticker gets more eyes on it.
Understood but you have to start looking at this as a buyout target. A big player could and would ramp up sales to capture more market share and triple those numbers IMO. The value is Fluticare and once approved - let the buyout negotiations commence AS cash from sales floods their coffers.